Over the past few years, raising money to test out ideas that could lead to new drugs had never been easier. Enthusiasm for new drugs that could treat common forms of cancer and rare inherited disorders has driven market caps for these three companies to substantial sums at a very early stage in their life cycle.
The biotechs in this list swelled in value even though they haven't presented much evidence that their new drug candidates actually work as intended for real people.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,